These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 4560843)

  • 1. Fibrinolytic enhancement by stanozolol: a double-blind trial.
    Davidson JF; McDonald GA; McNicol GP
    J Clin Pathol; 1972 Jul; 25(7):639. PubMed ID: 4560843
    [No Abstract]   [Full Text] [Related]  

  • 2. Fibrinolytic enhancement by stanozolol: a double blind trial.
    Davidson JF; Lochhead M; McDonald GA; McNicol GP
    Br J Haematol; 1972 May; 22(5):543-59. PubMed ID: 4555715
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical and laboratory double-blind investigation on effect of fibrinolytic therapy in patients with cutaneous vasculitis.
    Dodman B; Cunliffe WJ; Roberts BE; Sibbald R
    Br Med J; 1973 Apr; 2(5858):82-4. PubMed ID: 4573315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiopathic recurrent superficial thrombophlebitis: treatment with fibrinolytic enhancement.
    Jarrett PE; Morland M; Browse NL
    Br Med J; 1977 Apr; 1(6066):933-4. PubMed ID: 856391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical investigations on long-term activation of fibrinolysis by anabolic steroids.
    Bielawiec M; Bodzenta A; Lukjan H; Kiersnowska-Rogowska B; Kłoczko J; Myśliwiec M; Dabrowski S; Tymiński W; Czestochowska E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1986; 113(1-2):223-9. PubMed ID: 2427405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of phenformin plus stanozolol on fibrinolysis, platelet adhesiveness and blood lipids in patients with recurrent venous thrombosis.
    Bielawiec M; Myśliwiec M; Perzanowski A
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1974; 101(3):483-8. PubMed ID: 4139068
    [No Abstract]   [Full Text] [Related]  

  • 7. The effect of combined treatment with phenformin and stanazolol on blood lipids and fibrinolytic activity in patients with hypertriglyceridaemia.
    Ciświcka-Sznajderman M; Berent H; Rymaszewski Z
    Atherosclerosis; 1974; 19(1):153-9. PubMed ID: 4359182
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of phenformin and ethyloestrenol or stanozolol in the treatment of decreased fibrinolytic states. (Cutaneous vasculitis, Raynaud's disease, Behcet's syndrome, recurrent deep vein thrombosis and post myocardial infarction).
    Menon IS
    Acta Univ Carol Med Monogr; 1972; 52():19-23. PubMed ID: 4669824
    [No Abstract]   [Full Text] [Related]  

  • 9. Prophylaxis of recurrent venous thrombosis with long-term enhancement of fibrinolysis.
    Bielawiec M; Lukjan H; Myśliwiec M; Dabrowski S
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1979; 106(5-6):971-6. PubMed ID: 94894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibrinolytic enhancement by stanozolol--a two year study.
    Davidson JF; McDonald GA; Conkie JA
    Br J Haematol; 1972 May; 22(5):639-40. PubMed ID: 5032111
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of increasing fibrinolysis in patients with rheumatoid arthritis: a double blind study of stanozolol.
    Belch JJ; Madhok R; McArdle B; McLaughlin K; Kluft C; Forbes CD; Sturrock RD
    Q J Med; 1986 Jan; 58(225):19-27. PubMed ID: 3517926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The 131I-fibrinogen turnover during activation of blood fibrinolysis].
    Grabowski R; Bielawiec M; Kiersnowska B; Lukjan H; Perzanowski A; Mysliwiec M; Korfel B; Rogowski F
    Z Gesamte Inn Med; 1976 Dec; 31(24):1025-7. PubMed ID: 1020408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenformin and stanozolol in blood fibrinolytic activity.
    Menon IS; Cunliffe WJ; Weightman D; Dewar HA
    Br Med J; 1970 Feb; 1(5693):428. PubMed ID: 4244848
    [No Abstract]   [Full Text] [Related]  

  • 14. Behçet's syndrome and oral fibrinolytic therapy.
    Cunliffe WJ; Roberts BE; Dodman B
    Br Med J; 1973 May; 2(5864):486-7. PubMed ID: 4712497
    [No Abstract]   [Full Text] [Related]  

  • 15. Fibrinolytic enhancement with stanozolol fails to improve symptoms and signs in patients with post-surgical back pain.
    Cooper RG; Mitchell WS; Illingworth KJ; Jayson MI
    Scand J Rheumatol; 1991; 20(6):414-8. PubMed ID: 1837614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of oral stanozolol used in the prevention of postoperative deep vein thrombosis on fibrinolytic activity.
    Sue-Ling HM; Davies JA; Prentice CR; Verheijen JH; Kluft C
    Thromb Haemost; 1985 Feb; 53(1):141-2. PubMed ID: 3873118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Raynaud's phenomenon by fibrinolytic enhancement.
    Jarrett PE; Morland M; Browse NL
    Br Med J; 1978 Aug; 2(6136):523-5. PubMed ID: 698554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind trial of intramuscular stanozolol in the prevention of postoperative deep vein thrombosis following elective abdominal surgery.
    Blamey SL; McArdle BM; Burns P; Carter DC; Lowe GD; Forbes CD
    Thromb Haemost; 1984 Feb; 51(1):71-4. PubMed ID: 6539002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind randomized trial of perioperative fibrinolytic enhancement for femoropopliteal bypass.
    Berridge DC; Frier M; Westby JC; Hopkinson BR; Makin GS
    Br J Surg; 1991 Jan; 78(1):101-4. PubMed ID: 1998848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New trends in the treatment of trophic sequelae post-phlebitic syndrome].
    Agus GB; Sarcina A; Lorenzi G; Gabrielli L; Tantalo V
    Minerva Med; 1981 Oct; 72(42):2805-8. PubMed ID: 7031512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.